Skip to content

Markers in the Diagnosis of TIA

Markers in the Diagnosis of TIA

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01954329
Acronym
MIND-TIA
Enrollment
350
Registered
2013-10-01
Start date
2013-09-30
Completion date
Unknown
Last updated
2015-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transient Ischemic Attack

Keywords

Biomarkers, TIA, Diagnosis

Brief summary

MIND-TIA is primarily an observational diagnostic study that aims to evaluate the role of novel biomarkers in the diagnosis of Transient Ischemic Attack (TIA)in primary care. Rapid and adequate diagnosis of TIA is of great importance to enable a rapid start of treatment, and thereby decrease the risk of subsequent ischemic stroke.

Detailed description

Rationale: A Transient Ischaemic Attack (TIA) does not cause permanent damage of brain tissue, but the risk of a subsequent ischemic stroke in the short term is high. Timely recognition of TIA would result in early treatment and reduce the risk of ischaemic stroke, and other adverse cardiovascular events. To improve the management of TIA adequate diagnosis is of imminent importance. However the diagnosis is notoriously difficult, for both GP and neurologist. Adequate biomarkers for brain ischaemia could improve the early diagnosis and thus the subsequent management of TIA. Objectives: 1. To assess the added diagnostic value of biomarkers beyond the clinical assessment (medical history, signs and symptoms) in patients suspected of TIA. Secondary objectives 2. To assess the prognostic value of biomarkers in patients with an established diagnosis of TIA. 3. To assess the time delay and factors related to delay in patients suspected of TIA. Study population: 350 adult persons suspected of TIA from primary care. Methods: Recruitment of patients will be performed at the general practices of 200 GPs in the vicinity of 4 to 5 participating hospitals. During a home visit a research nurse collects a blood sample, and takes two health-related questionnaires. Participants will be referred by their GP to the regional TIA outpatient clinic for additional investigations, including brain imaging. The diagnostic accuracy of a set of biomarkers will be assessed with the 'definite' diagnosis of TIA by a panel of neurologists as the reference standard.

Interventions

None listed

Sponsors

Saltro, diagnostic center for primary care.
CollaboratorUNKNOWN
UMC Utrecht
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Being adult (18 years and older) * Presenting to the GP with a new episode of symptoms suspected of TIA and the GP considering further investigations to confirm or exclude TIA at the TIA outpatient clinic. * A blood sample can be collected within 72 hours after onset of symptoms.

Exclusion criteria

* The patient still has active symptoms or signs suspected of an ongoing ischemic stroke and immediate referral to the neurologist seems indicated. * Valid history taking is impossible because of severe cognitive impairment or insufficient knowledge of the Dutch language. * Patient with a life expectancy of \< 6 months. * Patient is not willing or able to give written informed consent

Design outcomes

Primary

MeasureTime frameDescription
'Definite' Diagnosis of TIAAfter 6 months of follow-upDetermined by expert panel consisting of 3 neurologists

Secondary

MeasureTime frameDescription
Ischemic stroke and other cardiovascular eventsDuring 6 months of follow-upAssessed in the medical records of the GPs
Time delay to GP consultation and start of treatment1 day of home visit

Countries

Netherlands

Contacts

Primary ContactLouis Servaas Dolmans, MD
L.S.Dolmans@umcutrecht.nl+31-88-7568159

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 16, 2026